InvestorsHub Logo
Followers 2
Posts 1360
Boards Moderated 0
Alias Born 01/05/2018

Re: None

Tuesday, 03/15/2022 9:40:18 AM

Tuesday, March 15, 2022 9:40:18 AM

Post# of 21540
"Our work published today suggests we may be able to broaden the possible applicability of Bryostatin to more complicated dementias with more than one pathology beyond AD, such as Parkinson's, multi-infarct dementia, and Multiple Sclerosis."

https://www.prnewswire.com/news-releases/synaptogenix-to-present-research-highlighting-potential-broad-applicability-for-lead-compound-bryostatin-at-the-international-conference-on-alzheimers-and-parkinsons-diseases-adpd-2022-301502928.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNPX News